MX2009011089A - Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. - Google Patents

Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.

Info

Publication number
MX2009011089A
MX2009011089A MX2009011089A MX2009011089A MX2009011089A MX 2009011089 A MX2009011089 A MX 2009011089A MX 2009011089 A MX2009011089 A MX 2009011089A MX 2009011089 A MX2009011089 A MX 2009011089A MX 2009011089 A MX2009011089 A MX 2009011089A
Authority
MX
Mexico
Prior art keywords
compounds
formula
adp receptor
platelet adp
antagonists
Prior art date
Application number
MX2009011089A
Other languages
English (en)
Spanish (es)
Inventor
Marc Nazare
Melitta Just
Gerhard Hessler
Joerg Czech
Gernot Zech
Tilo Weiss
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009011089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009011089A publication Critical patent/MX2009011089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011089A 2007-04-23 2008-04-09 Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. MX2009011089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07008209 2007-04-23
PCT/EP2008/002790 WO2008128647A1 (en) 2007-04-23 2008-04-09 Quinoline-carboxamide derivatives as p2y12 antagonists

Publications (1)

Publication Number Publication Date
MX2009011089A true MX2009011089A (es) 2009-10-30

Family

ID=38462433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011089A MX2009011089A (es) 2007-04-23 2008-04-09 Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.

Country Status (18)

Country Link
US (1) US8669266B2 (OSRAM)
EP (1) EP2148871A1 (OSRAM)
JP (1) JP5309131B2 (OSRAM)
KR (1) KR20100015886A (OSRAM)
CN (1) CN101663293B (OSRAM)
AR (1) AR066225A1 (OSRAM)
AU (1) AU2008241091B2 (OSRAM)
BR (1) BRPI0810462A2 (OSRAM)
CA (1) CA2684644A1 (OSRAM)
CL (1) CL2008001157A1 (OSRAM)
IL (1) IL201620A (OSRAM)
MX (1) MX2009011089A (OSRAM)
MY (1) MY153427A (OSRAM)
PA (1) PA8777901A1 (OSRAM)
PE (1) PE20090241A1 (OSRAM)
TW (1) TW200848042A (OSRAM)
UY (1) UY31039A1 (OSRAM)
WO (1) WO2008128647A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438491C (en) 2001-02-28 2012-11-27 Uroteq Inc. Method of making lubricious anti-microbial polymeric surfaces
US8288371B2 (en) 2007-10-05 2012-10-16 Pharmacopeia, Llc Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation
HRP20120735T1 (hr) 2007-11-29 2012-10-31 Actelion Pharmaceuticals Ltd. Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
ES2567311T3 (es) 2009-04-08 2016-04-21 Actelion Pharmaceuticals Ltd. 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 ３－（ビアリールオキシ）プロピオン酸誘導体
AR079451A1 (es) * 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
EP2725025A1 (fr) * 2012-10-26 2014-04-30 Sanofi Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12
TWI630203B (zh) 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
DE102015217396B4 (de) 2014-09-11 2018-07-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
EP3484881B1 (en) * 2016-07-14 2020-04-29 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
PL3515924T3 (pl) 2016-09-22 2022-04-11 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
BR112019014567A2 (pt) 2017-03-15 2020-02-18 Idorsia Pharmaceuticals Ltd Antagonista do receptor p2y12 ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de éster butílico do ácido
CN107648607A (zh) * 2017-09-11 2018-02-02 南昌大学 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023108363A1 (en) * 2021-12-13 2023-06-22 Beijing Honghui Meditech Co., Ltd Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition
CN115429874A (zh) * 2022-09-20 2022-12-06 暨南大学 水蛭素靶向并抑制dpp4治疗糖尿病

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
EP1578423B1 (en) * 2002-12-11 2010-08-18 Bayer Schering Pharma Aktiengesellschaft 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
KR20060041254A (ko) 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
US7157445B2 (en) * 2004-02-26 2007-01-02 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
JP4976394B2 (ja) * 2005-08-17 2012-07-18 シェーリング コーポレイション 新規な高親和性のキノリンベースのキナーゼリガンド

Also Published As

Publication number Publication date
AU2008241091B2 (en) 2013-05-09
BRPI0810462A2 (pt) 2014-10-14
IL201620A0 (en) 2010-05-31
PE20090241A1 (es) 2009-04-03
WO2008128647A1 (en) 2008-10-30
US8669266B2 (en) 2014-03-11
KR20100015886A (ko) 2010-02-12
US20100135999A1 (en) 2010-06-03
CN101663293A (zh) 2010-03-03
MY153427A (en) 2015-02-13
AU2008241091A1 (en) 2008-10-30
PA8777901A1 (es) 2008-11-19
JP5309131B2 (ja) 2013-10-09
HK1141803A1 (en) 2010-11-19
AR066225A1 (es) 2009-08-05
CA2684644A1 (en) 2008-10-30
JP2010524984A (ja) 2010-07-22
UY31039A1 (es) 2008-11-28
CL2008001157A1 (es) 2008-11-03
CN101663293B (zh) 2013-07-31
TW200848042A (en) 2008-12-16
IL201620A (en) 2013-11-28
EP2148871A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
MX2009011089A (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A3 (en) Heterocyclic pyrazole-carboxamides as p2y12 antagonists
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
WO2009010454A3 (en) Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2008080844A9 (en) Azaspiro derivatives
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
WO2007085833A3 (en) Pyrimidine derivatives
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
TW200833326A (en) Chemical compounds 572
WO2009080638A3 (en) Sulfamides as zap-70 inhibitors
WO2008107481A8 (en) 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
NO20083919L (no) Pyridin- og pyrimidinderivater som mGluR2-antagonister
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
IL202758A (en) Pyrol derivatives as p2y12 antagonists
WO2008077810A3 (en) Spiro-piperidine derivatives
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders

Legal Events

Date Code Title Description
FG Grant or registration